Patents by Inventor Stéphanie Polderdijk

Stéphanie Polderdijk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10351619
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: July 16, 2019
    Assignee: Cambridge Enterprise Limited
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Publication number: 20180273610
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 27, 2018
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Patent number: 9982035
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 29, 2018
    Assignee: Cambridge Enterprise Limited
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Publication number: 20160311887
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Application
    Filed: December 15, 2014
    Publication date: October 27, 2016
    Applicant: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin